Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Recruiting

Back to Small-cell Lung Cancer trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

Trial locations(2 sites)

United States

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

University of Maryland, Baltimore

Collaborators

Cardiff Oncology, National Cancer Institute (NCI)

Enrollment target

~37 participants

Started

July 2022

Primary completion

August 2027

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer — Stella